The outcome of @entity791 ( @entity791 ) has improved since the era of highly active antiretroviral therapy, but median survival remains low. We studied dose-adjusted EPOCH ( @entity2879 , @entity229 , @entity1891 , @entity786 , and @entity632 ) with suspension of antiretroviral therapy in 39 newly diagnosed @entity791 and examined protein expression profiles associated with drug resistance and histogenesis, @entity1 immunity, and @entity645 dynamics and mutations. The expression profiles from a subset of ARL cases were also compared with a matched group of similarly treated @entity645 -negative cases. Complete remission was achieved in 74% of @entity1 , and at 53 months median follow-up, disease-free and overall survival are 92% and 60%, respectively. Following reinstitution of antiretroviral therapy after chemotherapy, the @entity404 + cells recovered by 12 months and the viral loads decreased below baseline by 3 months. Compared with @entity645 -negative cases, the ARL cases had lower bcl-2 and higher CD10 expression, consistent with a germinal center origin and good prognosis, but were more likely to be highly proliferative and to express p53, adverse features with standard chemotherapy. Unlike @entity645 -negative cases, p53 overexpression was not associated with a poor outcome, suggesting different pathogenesis. High @entity5 proliferation did not correlate with poor outcome and may partially explain the high activity of dose-adjusted EPOCH. The results suggest that the improved immune function associated with highly active antiretroviral therapy (HAART) may have led to a shift in pathogenesis away from lymphomas of post-germinal center origin, which have a poor prognosis. These results suggest that @entity5 pathogenesis is responsible for the improved outcome of @entity791 in the era of HAART.

Highly effective treatment of XXXX with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and @entity5 biology.

@entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity404 :: ('920', 'Gene') :: ['CD4'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity645 :: ('57667', 'Species') :: ['HIV'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine'] @entity791 :: ('MESH:D000163', 'Disease') :: ['ARLs', 'acquired immunodeficiency syndrome-related lymphomas']
@entity791 :: (MESH:D000163,Disease) :: ['acquired immunodeficiency syndrome-related lymphoma']
